Research programme: drug discovery - Actelion

Drug Profile

Research programme: drug discovery - Actelion

Alternative Names: Actelion-4; Actelion-5; Actelion-6; Actelion-7

Latest Information Update: 02 Feb 2017

Price : $50

At a glance

  • Originator Actelion Pharmaceuticals
  • Class
  • Mechanism of Action Aspartic endopeptidase modulators; Ion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders; CNS disorders; Immunological disorders
  • Research Cancer; Infections

Most Recent Events

  • 02 Feb 2017 Preclinical research in Immunological disorders is still ongoing in Switzerland
  • 23 Jan 2017 Actelion Pharmaceuticals and Enamine enter into a collaboration agreement for the discovery and development of therapies for cardiovascular, central nervous system and immunological disorders, infectious diseases and cancer
  • 23 Jan 2017 Early research in Infections and Cancer in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top